MaloneyDG, Grillo-LopezAJ, BodkinDJ. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol1997; 15:3266–74.
2.
MaloneyDG, Grillo-LopezAJ, WhiteCA. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood1997; 90:2188–95.
3.
DavisTA, Grillo-LopezAJ, WhiteCA. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol2000; 18:3135–43.
4.
ChuE, DeVitaVT. Rituximab. In: Physicians' cancer chemotherapy drug manual 2007. Sudbury, MA: Jones and Bartlett Publishers, 2007: 315–8.
5.
NaranjoCA, BustoU, SellersEM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30:239–45.
